ハトウ　タイ   HATO Tai   羽藤　泰    所属   埼玉医科大学  医学部 総合医療センター　呼吸器外科    職種   准教授
論文種別	学術雑誌(総説)
言語種別	英語
査読の有無	査読あり
招待の有無	招待あり
表題	Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
掲載誌名	正式名：Immunotherapy 略　 称：Immunotherapy
掲載区分	国外
巻・号・頁	8(3),299-313頁
著者・共著者	Hato Tai, Zhu Andrew X, Duda Dan G
発行年月	2016
概要	Hepatocellular carcinoma (HCC) is a fatal disease with rising incidence in the world. For advanced HCC, sorafenib, a multikinase inhibitor, is the only systemic therapy with proven survival benefits. Sorafenib is a pan-VEGF receptor inhibitor, and thus many studies have focused its antivascular effects. But VEGF also acts as an immunosuppressive molecule. VEGF can inhibit maturation of dendritic cells, promote immune suppressive cell infiltration and enhance immune checkpoint molecules expression. On the other hand, potent VEGF inhibition may increase tumor hypoxia, which could hinder antitumor immunity or immunotherapy. Thus, achieving synergy when combining anti-VEGF therapy with immunotherapy may require proper polarization of the tumor microenvironment by dose titration or combination with other immunomodulating agents.
DOI	10.2217/imt.15.126
PMID	26865127